MECOM is mutated in 1.51% of acute myeloid leukemia patients [3].

MECOM is an inclusion criterion in 117 clinical trials for acute myeloid leukemia, of which 93 are open and 24 are closed. Of the trials that contain MECOM status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 33 are phase 1 (25 open), 24 are phase 1/phase 2 (19 open), 47 are phase 2 (38 open), 3 are phase 2/phase 3 (3 open), 7 are phase 3 (5 open), and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 0.88% of myelodysplastic syndromes patients [3].

MECOM is an inclusion criterion in 95 clinical trials for myelodysplastic syndromes, of which 82 are open and 13 are closed. Of the trials that contain MECOM status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 26 are phase 1 (21 open), 18 are phase 1/phase 2 (16 open), 39 are phase 2 (33 open), 2 are phase 2/phase 3 (2 open), 6 are phase 3 (6 open), and 3 are no phase specified (3 open) [4].

Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in myelodysplastic syndromes trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 3.94% of acute lymphoblastic leukemia patients [3].

MECOM is an inclusion criterion in 47 clinical trials for acute lymphoblastic leukemia, of which 38 are open and 9 are closed. Of the trials that contain MECOM status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 13 are phase 1 (8 open), 5 are phase 1/phase 2 (4 open), 23 are phase 2 (20 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in acute lymphoblastic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 32 clinical trials for chronic myeloid leukemia, of which 26 are open and 6 are closed. Of the trials that contain MECOM status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (6 open), 5 are phase 1/phase 2 (5 open), 14 are phase 2 (12 open), and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in chronic myeloid leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 25 clinical trials for chronic myelomonocytic leukemia, of which 21 are open and 4 are closed. Of the trials that contain MECOM status and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (5 open), 6 are phase 1/phase 2 (5 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [4].

Fludarabine, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in chronic myelomonocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 18 clinical trials for hodgkin lymphoma, of which 13 are open and 5 are closed. Of the trials that contain MECOM status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is no phase specified (1 open) [4].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in hodgkin lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 1.16% of non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 17 clinical trials for non-hodgkin lymphoma, of which 12 are open and 5 are closed. Of the trials that contain MECOM status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is no phase specified (1 open) [4].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in non-hodgkin lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 17 clinical trials for multiple myeloma, of which 15 are open and 2 are closed. Of the trials that contain MECOM status and multiple myeloma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), 9 are phase 2 (9 open), and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 13 clinical trials for acute biphenotypic leukemia, of which 8 are open and 5 are closed. Of the trials that contain MECOM status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 6 are phase 2 (4 open), and 1 is no phase specified (1 open) [4].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in acute biphenotypic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 12 clinical trials for Burkitt lymphoma, of which 11 are open and 1 is closed. Of the trials that contain MECOM status and Burkitt lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in Burkitt lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 1.51% of acute leukemia patients [3].

MECOM is an inclusion criterion in 11 clinical trials for acute leukemia, of which 10 are open and 1 is closed. Of the trials that contain MECOM status and acute leukemia as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is no phase specified (1 open) [4].

Cyclophosphamide, total-body irradiation, and mycophenolate mofetil are the most frequent therapies in acute leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 0.62% of chronic lymphocytic leukemia patients [3].

MECOM is an inclusion criterion in 11 clinical trials for chronic lymphocytic leukemia, of which 8 are open and 3 are closed. Of the trials that contain MECOM status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in chronic lymphocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 11 clinical trials for mantle cell lymphoma, of which 10 are open and 1 is closed. Of the trials that contain MECOM status and mantle cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in mantle cell lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 3.17% of follicular lymphoma patients [3].

MECOM is an inclusion criterion in 10 clinical trials for follicular lymphoma, of which 10 are open and 0 are closed. Of the trials that contain MECOM status and follicular lymphoma as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in follicular lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 10 clinical trials for marginal zone lymphoma, of which 10 are open and 0 are closed. Of the trials that contain MECOM status and marginal zone lymphoma as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in marginal zone lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 10 clinical trials for myelofibrosis, of which 9 are open and 1 is closed. Of the trials that contain MECOM status and myelofibrosis as inclusion criteria, 2 are early phase 1 (2 open), 4 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [4].

Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in myelofibrosis trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 10 clinical trials for myeloproliferative neoplasm, of which 9 are open and 1 is closed. Of the trials that contain MECOM status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 2 are no phase specified (2 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in myeloproliferative neoplasm trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 9 clinical trials for anaplastic large cell lymphoma, of which 9 are open and 0 are closed. Of the trials that contain MECOM status and anaplastic large cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 2 are no phase specified (2 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in anaplastic large cell lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 2.61% of lymphoma patients [3].

MECOM is an inclusion criterion in 7 clinical trials for lymphoma, of which 6 are open and 1 is closed. Of the trials that contain MECOM status and lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

Total-body irradiation, cyclophosphamide, and fludarabine are the most frequent therapies in lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 0.57% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].

MECOM is an inclusion criterion in 7 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 7 are open and 0 are closed. Of the trials that contain MECOM status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 5 are phase 2 (5 open) and 2 are no phase specified (2 open) [4].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in chronic lymphocytic leukemia/small lymphocytic lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 4 are open and 3 are closed. Of the trials that contain MECOM status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

Cyclophosphamide, allogeneic hematopoietic stem cell transplantation, and tacrolimus are the most frequent therapies in juvenile myelomonocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 7 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 6 are open and 1 is closed. Of the trials that contain MECOM status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [4].

Cyclophosphamide, total-body irradiation, and fludarabine are the most frequent therapies in myelodysplastic/myeloproliferative neoplasm trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 7 clinical trials for prolymphocytic leukemia, of which 7 are open and 0 are closed. Of the trials that contain MECOM status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 2 are no phase specified (2 open) [4].

Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in prolymphocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 6 clinical trials for lymphoplasmacytic lymphoma, of which 6 are open and 0 are closed. Of the trials that contain MECOM status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (4 open) and 2 are no phase specified (2 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in lymphoplasmacytic lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain MECOM status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

Fludarabine, mycophenolate mofetil, and tacrolimus are the most frequent therapies in small lymphocytic lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 1.89% of diffuse large B-cell lymphoma patients [3].

MECOM is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MECOM status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [4].

Allogeneic hematopoietic stem cell transplantation, antineoplastic immune cell, and bet inhibitor ft-1101 are the most frequent therapies in diffuse large B-cell lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 1.82% of B-cell non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MECOM status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [4].

Bet inhibitor ft-1101, cdk9 inhibitor azd4573, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MECOM status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

Fludarabine, tacrolimus, and rituximab are the most frequent therapies in double-hit lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 4 clinical trials for lymphoblastic lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MECOM status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in lymphoblastic lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 4 clinical trials for plasma cell leukemia, of which 3 are open and 1 is closed. Of the trials that contain MECOM status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in plasma cell leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 4 clinical trials for primary myelofibrosis, of which 3 are open and 1 is closed. Of the trials that contain MECOM status and primary myelofibrosis as inclusion criteria, 4 are phase 2 (3 open) [4].

Fludarabine, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in primary myelofibrosis trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 4 clinical trials for refractory anemia with excess blasts, of which 3 are open and 1 is closed. Of the trials that contain MECOM status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

Azacitidine, autologous nkg2d car-expressing t-lymphocytes cm-cs1, and prima-1 analog apr-246 are the most frequent therapies in refractory anemia with excess blasts trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 3 clinical trials for refractory anemia with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain MECOM status and refractory anemia with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [4].

Cytarabine, hedgehog inhibitor pf-04449913, and stemregenin-1 expanded umbilical cord blood transplant are the most frequent therapies in refractory anemia with excess blasts-2 trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MECOM status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (3 open) [4].

Cyclophosphamide, fludarabine, and mesna are the most frequent therapies in T-cell lymphoblastic leukemia/lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 3 clinical trials for T-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MECOM status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

Cdk9 inhibitor azd4573, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in T-cell non-hodgkin lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 18.15% of malignant solid tumor patients [3].

MECOM is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) [4].

Busulfan, cyclophosphamide, and fludarabine are the most frequent therapies in malignant solid tumor trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for acute leukemia of ambiguous lineage, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and acute leukemia of ambiguous lineage as inclusion criteria, 2 are phase 2 (2 open) [4].

Cyclosporine, mycophenolate mofetil, and hematopoietic progenitor cells from cord blood are the most frequent therapies in acute leukemia of ambiguous lineage trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (1 open) [4].

Anti-cd123 adc imgn632, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in acute promyelocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

Anti-cd123 adc imgn632, cyclosporine, and filgrastim are the most frequent therapies in blastic plasmacytoid dendritic cell neoplasm trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

Busulfan, cyclophosphamide, and fludarabine are the most frequent therapies in Burkitt leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and hematopoietic and lymphoid malignancy as inclusion criteria, 2 are phase 2 (2 open) [4].

Fludarabine, thiotepa, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in hematopoietic and lymphoid malignancy trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].

Cyclophosphamide, fludarabine, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in mature T-cell and NK-cell lymphoma/leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and mature T-cell and NK-cell neoplasm as inclusion criteria, 2 are phase 2 (2 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in mature T-cell and NK-cell neoplasm trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for myeloid sarcoma, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and myeloid sarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

Fludarabine, non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, and sorafenib are the most frequent therapies in myeloid sarcoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

Cyclophosphamide, mesna, and non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation are the most frequent therapies in natural killer cell lymphoblastic leukemia/lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, antineoplastic immune cell, and autologous hematopoietic stem cell transplatation are the most frequent therapies in peripheral T-cell lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for refractory anemia, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and refractory anemia as inclusion criteria, 2 are phase 2 (1 open) [4].

Deferasirox, stemregenin-1 expanded umbilical cord blood transplant, and cytarabine are the most frequent therapies in refractory anemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 2 clinical trials for secondary myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and secondary myelofibrosis as inclusion criteria, 2 are phase 2 (1 open) [4].

MECOM is an inclusion criterion in 2 clinical trials for small lymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and small lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) [4].

Cdk9 inhibitor azd4573, busulfan, and clofarabine are the most frequent therapies in small lymphocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 6.12% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

MECOM is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in mature T-cell and NK-cell non-hodgkin lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 4.17% of rhabdomyosarcoma patients [3].

MECOM is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in rhabdomyosarcoma trials with MECOM alterations as inclusion criteria [4].

MECOM is mutated in 3.64% of neuroblastoma patients [3].

MECOM is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in neuroblastoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute erythroid leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute megakaryoblastic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and rivogenlecleucel are the most frequent therapies in acute myeloid leukemia with myelodysplasia-related changes trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute undifferentiated leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in adult acute lymphoblastic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in adult T-cell leukemia/lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for aggressive non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and aggressive non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Cyclosporine, filgrastim, and mycophenolate mofetil are the most frequent therapies in aggressive non-hodgkin lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in B-cell prolymphocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 2 (1 open) [4].

Deferasirox is the most frequent therapy in chronic myelomonocytic leukemia-1 trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in desmoplastic small round cell tumor trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in Ewing sarcoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in mature B-cell lymphoma/leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in mediastinal large B-cell lymphoma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Allogeneic bone marrow transplantation, busulfan, and cyclophosphamide are the most frequent therapies in mixed phenotype acute leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

Busulfan, fludarabine, and venetoclax are the most frequent therapies in myelodysplastic/myeloproliferative neoplasm, unclassifiable trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for myeloma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in myeloma trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in plasma cell neoplasm trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in polycythemia vera trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for refractory anemia with ring sideroblasts, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and refractory anemia with ring sideroblasts as inclusion criteria, 1 is phase 2 (1 open) [4].

Deferasirox is the most frequent therapy in refractory anemia with ring sideroblasts trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

Cdk9 inhibitor azd4573 is the most frequent therapy in Richter syndrome trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Ect-001 expanded cord blood is the most frequent therapy in secondary acute myeloid leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in secondary myelodysplastic syndrome trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in T-cell prolymphocytic leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

Anti-thymocyte globulin, cyclophosphamide, and fludarabine are the most frequent therapies in T-cell and NK-cell neoplasm trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Ect-001 expanded cord blood is the most frequent therapy in therapy-related acute myeloid leukemia trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

Family-mismatched/haploidentical donor, mismatched unrelated donor, and peripheral blood stem cell transplantation are the most frequent therapies in therapy-related myeloid neoplasm trials with MECOM alterations as inclusion criteria [4].

MECOM is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in waldenstrom macroglobulinemia trials with MECOM alterations as inclusion criteria [4].